Literature DB >> 10653587

Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells.

K M Darcy1, D Zangani, A L Wohlhueter, R Y Huang, M M Vaughan, J A Russell, M M Ip.   

Abstract

Studies were undertaken to examine the natural role of ErbB2, ErbB3, and ErbB4 during the development of normal rat mammary epithelial cells (MECs) in vivo and in vitro. Immunohistochemical analysis demonstrated that mammary gland terminal end buds expressed abundant ErbB2 and ErbB4 but limited ErbB3 in pubescent rats, whereas luminal epithelial cells in nulliparous rats expressed ErbB2, ErbB3, and/or ErbB4. During pregnancy, ductal epithelial cells and stromal cells expressed abundant ErbB3 but limited ErbB2. Although ErbB2 and ErbB3 were downregulated throughout lactation, both receptors were re-expressed during involution. In contrast, ErbB4 was downregulated throughout pregnancy, lactation, and involution. Immunoblotting and immunoprecipitation studies confirmed the developmental expression of ErbB2 and ErbB3 in the mammary gland and the co-localization of distinct ErbB receptors in the mammary gland of nulliparous rats. In agreement with our in vivo findings, primary culture studies demonstrated that ErbB2 and ErbB3 were expressed in functionally immature, terminally differentiated and apoptotic MECs, and downregulated in functionally differentiated MECs. ErbB receptor signaling was required for epithelial cell growth, functional differentiation, and morphogenesis of immature MECs, and the survival of terminally differentiated MECs. Finally, ErbB4 expression did not interfere with functional differentiation and apoptosis of normal MECs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653587     DOI: 10.1177/002215540004800107

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  16 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 2.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

3.  Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.

Authors:  Christian Dillon; Anna Creer; Karen Kerr; Angelika Kümin; Clive Dickson
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

4.  The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.

Authors:  Margot M Ip; Sibel O McGee; Patricia A Masso-Welch; Clement Ip; Xiaojing Meng; Lihui Ou; Suzanne F Shoemaker
Journal:  Carcinogenesis       Date:  2007-01-27       Impact factor: 4.944

Review 5.  Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network.

Authors:  K L Troyer; D C Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 6.  Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.

Authors:  Kathleen M Darcy; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2010-03-16       Impact factor: 5.482

7.  Antiproliferative effect of peripheral benzodiazepine receptor antagonist PK11195 in rat mammary tumor cells.

Authors:  Sutapa Mukhopadhyay; Bobby Guillory; Shyamali Mukherjee; Salil K Das
Journal:  Mol Cell Biochem       Date:  2010-03-04       Impact factor: 3.396

8.  Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu.

Authors:  Rebecca A Rozich; David R Mills; Kate E Brilliant; Helen M Callanan; DongQin Yang; Umadevi Tantravahi; Douglas C Hixson
Journal:  Exp Mol Pathol       Date:  2010-07-22       Impact factor: 3.362

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate.

Authors:  Howard Kendrick; Joseph L Regan; Fiona-Ann Magnay; Anita Grigoriadis; Costas Mitsopoulos; Marketa Zvelebil; Matthew J Smalley
Journal:  BMC Genomics       Date:  2008-12-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.